search
Back to results

Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients

Primary Purpose

Sickle Cell Disease, Iron Overload, Hemolytic Anemia

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Deferasirox (ICL670)
Deferoxamine (DFO)
Sponsored by
Novartis Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sickle Cell Disease focused on measuring Sickle Cell Disease, Iron Overload from Repeated Blood Transfusions, Iron Overload, Blood Transfusions

Eligibility Criteria

2 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age greater than or equal to 2 years Male or female patients with sickle cell disease (SS, SC, SD, Sβo or Sβ+ thalassemia) Iron overload from repeated blood transfusion, as defined by one of the following: For patients > 16 years old receiving simple transfusions: lifetime history of receipt of at least 120 ml/kg or 30 adult units of packed red blood cells, OR For patients ≤ 16 years old receiving simple transfusions: lifetime history of receipt of at least 120 ml/kg of packed red blood cells, OR For all patients receiving exchange transfusions in the absence of a previous attempt to achieve negative iron balance: lifetime performance of at least 20 procedures, OR For all patients: liver iron content ≥ 7 mg Fe/g dry weight as measured by biopsy, Magnetic Resonance Imaging (MRI), or magnetic susceptibility performed within 3 months prior to entry into screening For entry into the screening period: serum ferritin of ≥ 1000 µg/mL on at least two occasions during the prior year obtained in the absence of concomitant infection. Body weight > 10 kg No known allergy or contraindication to the administration of deferoxamine Ability to comply with all study-related procedures, medications, and evaluations Sexually active pre-menopausal female patients must use double-barrier contraception, oral contraceptive plus barrier contraceptive, or must have undergone clinically documented total hysterectomy and/or oophorectomy, tubal ligation or be postmenopausal defined by amenorrhea for at least 12 months. Written informed consent by the patient or for pediatric patient's consent of the patient's legal guardian. The definition of the term 'pediatric' for enrollment and study conduct will be in accordance with the local legislation. Exclusion Criteria: Serum creatinine above the upper limit of normal Significant proteinuria History of nephrotic syndrome Alanine aminotransferase (ALT) ≥ 250 U/L at screening Clinical evidence of active hepatitis B or hepatitis C History of HIV Fever or other signs/symptoms of infection within 10 days prior to the screening visit Uncontrolled systemic hypertension History of Myocardial Infarction, Congestive Heart Failure or unstable cardiac disease not controlled by standard medical therapy Clinically relevant cataract or a previous history of clinically relevant ocular toxicity related to iron chelation Presence of a surgical or medical condition that might significantly alter the absorption, distribution, metabolism or excretion of any study drug History of drug or alcohol abuse within the 12 months prior to enrollment Pregnant or breast feeding patients Patients treated with systemic investigational drug within 4 weeks prior or with topical investigational drug 7 days prior to the screening visit Randomization in a previous clinical trial involving ICL670 Other protocol-related inclusion / exclusion criteria may apply.

Sites / Locations

  • University of Alabama Pediatric Hematology/Oncology
  • University of Alabama Medical center
  • University of South Alabama Medical Center
  • University of South Alabama
  • Loma Linda University Medical Center
  • Children's Hospital Oakland
  • Center for Cancer and Blood Disorders
  • Children's National Medical Center
  • Howard University Hospital
  • Miami Children's Hospital
  • Tampa Children's Hospital at St Joseph's
  • Tampa Children's Hospital at St. Joseph's
  • H. Lee Muffit Cancer Center and Research Institute/James A. Haley Veterans Hospital
  • Emory University School of Medicine
  • Children's Healthcare of Atlanta at Scottish Rite
  • Adult Sickle Cell Clinic
  • Backus Children's Hospital
  • University of Illinois at Chicago
  • Children's Memorial Hospital
  • Pediatric Sickle Cell Program/James Whitcomb Riley Hospital for Children
  • St. Jude Children's Hospital Affiliate
  • Tulane University Sickle Cell Center
  • Children's Hospital
  • LSU Health Sciences Center/Carroll W. Feist Professor of Cancer Research
  • Brigham and Woman's Hospital/Harvard Medical School
  • Children's Hospital Boston
  • Children's Hospital
  • University of Michigan
  • Karmanos Cancer Institute
  • Washington University School of Medicine
  • Sickle Cell Center, Montefiore Hospital
  • SUNY Downstate Medical Center
  • New York Methodist Hospital
  • Weill Medical College of Cornell University
  • Columbia University
  • Carolinas Medical Transplant Center
  • University of Cincinnati
  • Children's Hospital Medical Center
  • The University of Oklahoma
  • Children's Hospital of Philadelphia
  • Pennsylvania Oncology/Hematology
  • Jefferson University
  • Drexel University College of Medicine
  • Children's Hospital of Pittsburgh
  • Hillman Cancer Center
  • Liberty Hematology Oncology Center
  • Palmetto Health Clinical Trials
  • Santee Hematology/Oncology
  • St Jude's Children's Research Hospital
  • St. Jude's Children Research Hospital
  • Cooks Children's Hospital
  • Texas Children's Hospital/Baylor College of Medicine
  • Scott and White Memorial Hospital & Clinics
  • Children's Hospital of the King's Daughter
  • Medical College of Virginia
  • Virginia Commonwealth University
  • University of Alberta
  • The Ottawa Hospital
  • Hopital Ste-Justine

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Deferasirox (ICL670)

Deferoxamine (DFO) then ICL670

Arm Description

Deferasirox (ICL670) 20 mg/kg orally once daily for 104 weeks.

Deferoxamine (DFO) subcutaneously for a weekly dose of 175 mg/kg for 24 weeks then crossed over to receive Deferasirox (ICL670) orally 20 mg/kg for a total of 104 weeks on therapy.

Outcomes

Primary Outcome Measures

The Number of Participants With Adverse Events (AEs) in the First 24 Weeks of Treatment
The number of participants with Adverse Events (AEs) overall and according to Medical Dictionary for Regulatory Activities (MedDRA) preferred term greater than or equal to 5% participants in any group by treatment in the first 24 weeks.

Secondary Outcome Measures

Absolute Change in Serum Ferritin From Baseline to Week 24
Absolute change from baseline serum ferritin after 24 weeks of treatment with Deferasirox (ICL670) and absolute change from baseline serum ferritin after 24 weeks of treatment with Deferoxamine. Means were adjusted for the amount of transfused blood.
Absolute Change in Serum Ferritin After Start of Treatment With Deferasirox (ICL670) to Week 24 and to Week 52
Absolute change in serum ferritin after start of treatment with Deferasirox (ICL670) to week 24 and the absolute change in serum ferritin after start of treatment with Deferasirox (ICL670) to week 52 for the Deferasirox treatment group and the Deferoxamine then Deferasirox treatment group. Means were adjusted for the amount of transfused blood.
Absolute Change in Serum Ferritin After Start of Treatment With Deferasirox (ICL670) to Week 104
Absolute change in serum ferritin after start of treatment with Deferasirox (ICL670) to week 104 for the Deferasirox treatment group. Means were adjusted for the amount of transfused blood.

Full Information

First Posted
May 10, 2005
Last Updated
May 23, 2011
Sponsor
Novartis Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT00110617
Brief Title
Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients
Official Title
A Randomized, Open-label, Multi-center, Phase II Study to Evaluate the Safety and Efficacy of Deferasirox (ICL670) 20 mg/kg/Day Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients With Iron Overload From Repeated Blood Transfusions
Study Type
Interventional

2. Study Status

Record Verification Date
May 2011
Overall Recruitment Status
Completed
Study Start Date
May 2005 (undefined)
Primary Completion Date
April 2008 (Actual)
Study Completion Date
April 2008 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Novartis Pharmaceuticals

4. Oversight

5. Study Description

Brief Summary
This study will examine the long-term safety and efficacy of Deferasirox in patients with sickle cell disease and iron overload from repeated blood transfusions.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sickle Cell Disease, Iron Overload, Hemolytic Anemia
Keywords
Sickle Cell Disease, Iron Overload from Repeated Blood Transfusions, Iron Overload, Blood Transfusions

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
212 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Deferasirox (ICL670)
Arm Type
Experimental
Arm Description
Deferasirox (ICL670) 20 mg/kg orally once daily for 104 weeks.
Arm Title
Deferoxamine (DFO) then ICL670
Arm Type
Experimental
Arm Description
Deferoxamine (DFO) subcutaneously for a weekly dose of 175 mg/kg for 24 weeks then crossed over to receive Deferasirox (ICL670) orally 20 mg/kg for a total of 104 weeks on therapy.
Intervention Type
Drug
Intervention Name(s)
Deferasirox (ICL670)
Intervention Description
Deferasirox was provided in 125 mg, 250 mg, and 500 mg dispersible tablets and was administered orally at an initial dose of 20 mg/kg/day.
Intervention Type
Drug
Intervention Name(s)
Deferoxamine (DFO)
Intervention Description
Deferoxamine was supplied in vials of 500 mg and 2000 mg administered subcutaneously for a weekly dose of 175 mg/kg.
Primary Outcome Measure Information:
Title
The Number of Participants With Adverse Events (AEs) in the First 24 Weeks of Treatment
Description
The number of participants with Adverse Events (AEs) overall and according to Medical Dictionary for Regulatory Activities (MedDRA) preferred term greater than or equal to 5% participants in any group by treatment in the first 24 weeks.
Time Frame
24 Weeks
Secondary Outcome Measure Information:
Title
Absolute Change in Serum Ferritin From Baseline to Week 24
Description
Absolute change from baseline serum ferritin after 24 weeks of treatment with Deferasirox (ICL670) and absolute change from baseline serum ferritin after 24 weeks of treatment with Deferoxamine. Means were adjusted for the amount of transfused blood.
Time Frame
Baseline, 24 Weeks
Title
Absolute Change in Serum Ferritin After Start of Treatment With Deferasirox (ICL670) to Week 24 and to Week 52
Description
Absolute change in serum ferritin after start of treatment with Deferasirox (ICL670) to week 24 and the absolute change in serum ferritin after start of treatment with Deferasirox (ICL670) to week 52 for the Deferasirox treatment group and the Deferoxamine then Deferasirox treatment group. Means were adjusted for the amount of transfused blood.
Time Frame
Start of Deferasirox (ICL670) treatment, 24 Weeks, 52 Weeks
Title
Absolute Change in Serum Ferritin After Start of Treatment With Deferasirox (ICL670) to Week 104
Description
Absolute change in serum ferritin after start of treatment with Deferasirox (ICL670) to week 104 for the Deferasirox treatment group. Means were adjusted for the amount of transfused blood.
Time Frame
Start of Deferasirox (ICL670) treatment, 104 Weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age greater than or equal to 2 years Male or female patients with sickle cell disease (SS, SC, SD, Sβo or Sβ+ thalassemia) Iron overload from repeated blood transfusion, as defined by one of the following: For patients > 16 years old receiving simple transfusions: lifetime history of receipt of at least 120 ml/kg or 30 adult units of packed red blood cells, OR For patients ≤ 16 years old receiving simple transfusions: lifetime history of receipt of at least 120 ml/kg of packed red blood cells, OR For all patients receiving exchange transfusions in the absence of a previous attempt to achieve negative iron balance: lifetime performance of at least 20 procedures, OR For all patients: liver iron content ≥ 7 mg Fe/g dry weight as measured by biopsy, Magnetic Resonance Imaging (MRI), or magnetic susceptibility performed within 3 months prior to entry into screening For entry into the screening period: serum ferritin of ≥ 1000 µg/mL on at least two occasions during the prior year obtained in the absence of concomitant infection. Body weight > 10 kg No known allergy or contraindication to the administration of deferoxamine Ability to comply with all study-related procedures, medications, and evaluations Sexually active pre-menopausal female patients must use double-barrier contraception, oral contraceptive plus barrier contraceptive, or must have undergone clinically documented total hysterectomy and/or oophorectomy, tubal ligation or be postmenopausal defined by amenorrhea for at least 12 months. Written informed consent by the patient or for pediatric patient's consent of the patient's legal guardian. The definition of the term 'pediatric' for enrollment and study conduct will be in accordance with the local legislation. Exclusion Criteria: Serum creatinine above the upper limit of normal Significant proteinuria History of nephrotic syndrome Alanine aminotransferase (ALT) ≥ 250 U/L at screening Clinical evidence of active hepatitis B or hepatitis C History of HIV Fever or other signs/symptoms of infection within 10 days prior to the screening visit Uncontrolled systemic hypertension History of Myocardial Infarction, Congestive Heart Failure or unstable cardiac disease not controlled by standard medical therapy Clinically relevant cataract or a previous history of clinically relevant ocular toxicity related to iron chelation Presence of a surgical or medical condition that might significantly alter the absorption, distribution, metabolism or excretion of any study drug History of drug or alcohol abuse within the 12 months prior to enrollment Pregnant or breast feeding patients Patients treated with systemic investigational drug within 4 weeks prior or with topical investigational drug 7 days prior to the screening visit Randomization in a previous clinical trial involving ICL670 Other protocol-related inclusion / exclusion criteria may apply.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Novartis Pharmaceuticals
Organizational Affiliation
Novartis Pharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
University of Alabama Pediatric Hematology/Oncology
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35233
Country
United States
Facility Name
University of Alabama Medical center
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294
Country
United States
Facility Name
University of South Alabama Medical Center
City
Mobile
State/Province
Alabama
ZIP/Postal Code
36604
Country
United States
Facility Name
University of South Alabama
City
Mobile
State/Province
Alabama
ZIP/Postal Code
36617
Country
United States
Facility Name
Loma Linda University Medical Center
City
Loma Linda
State/Province
California
ZIP/Postal Code
92354
Country
United States
Facility Name
Children's Hospital Oakland
City
Oakland
State/Province
California
ZIP/Postal Code
94609
Country
United States
Facility Name
Center for Cancer and Blood Disorders
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20010-2970
Country
United States
Facility Name
Children's National Medical Center
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20010
Country
United States
Facility Name
Howard University Hospital
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20059
Country
United States
Facility Name
Miami Children's Hospital
City
Miami
State/Province
Florida
ZIP/Postal Code
33155
Country
United States
Facility Name
Tampa Children's Hospital at St Joseph's
City
Tampa
State/Province
Florida
ZIP/Postal Code
33607-6387
Country
United States
Facility Name
Tampa Children's Hospital at St. Joseph's
City
Tampa
State/Province
Florida
ZIP/Postal Code
33607-6387
Country
United States
Facility Name
H. Lee Muffit Cancer Center and Research Institute/James A. Haley Veterans Hospital
City
Tampa
State/Province
Florida
ZIP/Postal Code
33612
Country
United States
Facility Name
Emory University School of Medicine
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30303
Country
United States
Facility Name
Children's Healthcare of Atlanta at Scottish Rite
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30342
Country
United States
Facility Name
Adult Sickle Cell Clinic
City
Augusta
State/Province
Georgia
ZIP/Postal Code
30912-3128
Country
United States
Facility Name
Backus Children's Hospital
City
Savannah
State/Province
Georgia
ZIP/Postal Code
31403
Country
United States
Facility Name
University of Illinois at Chicago
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States
Facility Name
Children's Memorial Hospital
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60614-3394
Country
United States
Facility Name
Pediatric Sickle Cell Program/James Whitcomb Riley Hospital for Children
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46202
Country
United States
Facility Name
St. Jude Children's Hospital Affiliate
City
Baton Rouge
State/Province
Louisiana
ZIP/Postal Code
70808
Country
United States
Facility Name
Tulane University Sickle Cell Center
City
New Orleans
State/Province
Louisiana
ZIP/Postal Code
70112
Country
United States
Facility Name
Children's Hospital
City
New Orleans
State/Province
Louisiana
ZIP/Postal Code
70118
Country
United States
Facility Name
LSU Health Sciences Center/Carroll W. Feist Professor of Cancer Research
City
Shreveport
State/Province
Louisiana
ZIP/Postal Code
71130
Country
United States
Facility Name
Brigham and Woman's Hospital/Harvard Medical School
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
Facility Name
Children's Hospital Boston
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
Facility Name
Children's Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
Facility Name
University of Michigan
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109-0238
Country
United States
Facility Name
Karmanos Cancer Institute
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48201
Country
United States
Facility Name
Washington University School of Medicine
City
St. Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Facility Name
Sickle Cell Center, Montefiore Hospital
City
Bronx
State/Province
New York
ZIP/Postal Code
10467-2490
Country
United States
Facility Name
SUNY Downstate Medical Center
City
Brooklyn
State/Province
New York
ZIP/Postal Code
11203
Country
United States
Facility Name
New York Methodist Hospital
City
Brooklyn
State/Province
New York
ZIP/Postal Code
11215
Country
United States
Facility Name
Weill Medical College of Cornell University
City
New York
State/Province
New York
ZIP/Postal Code
10021
Country
United States
Facility Name
Columbia University
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
Facility Name
Carolinas Medical Transplant Center
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28232
Country
United States
Facility Name
University of Cincinnati
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45219
Country
United States
Facility Name
Children's Hospital Medical Center
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
72764
Country
United States
Facility Name
The University of Oklahoma
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73104
Country
United States
Facility Name
Children's Hospital of Philadelphia
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104-4399
Country
United States
Facility Name
Pennsylvania Oncology/Hematology
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19106
Country
United States
Facility Name
Jefferson University
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States
Facility Name
Drexel University College of Medicine
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19134-1095
Country
United States
Facility Name
Children's Hospital of Pittsburgh
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States
Facility Name
Hillman Cancer Center
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15232
Country
United States
Facility Name
Liberty Hematology Oncology Center
City
Columbia
State/Province
South Carolina
ZIP/Postal Code
29203
Country
United States
Facility Name
Palmetto Health Clinical Trials
City
Columbia
State/Province
South Carolina
ZIP/Postal Code
29203
Country
United States
Facility Name
Santee Hematology/Oncology
City
Sumter
State/Province
South Carolina
ZIP/Postal Code
29150
Country
United States
Facility Name
St Jude's Children's Research Hospital
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38105-2794
Country
United States
Facility Name
St. Jude's Children Research Hospital
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38105
Country
United States
Facility Name
Cooks Children's Hospital
City
Fort Worth
State/Province
Texas
ZIP/Postal Code
76104-2724
Country
United States
Facility Name
Texas Children's Hospital/Baylor College of Medicine
City
Houston
State/Province
Texas
ZIP/Postal Code
77030-2399
Country
United States
Facility Name
Scott and White Memorial Hospital & Clinics
City
Temple
State/Province
Texas
ZIP/Postal Code
76508
Country
United States
Facility Name
Children's Hospital of the King's Daughter
City
Norfolk
State/Province
Virginia
ZIP/Postal Code
23507
Country
United States
Facility Name
Medical College of Virginia
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23298-0306
Country
United States
Facility Name
Virginia Commonwealth University
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23298-0646
Country
United States
Facility Name
University of Alberta
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6G 2H7
Country
Canada
Facility Name
The Ottawa Hospital
City
Ottawa
State/Province
Ontario
ZIP/Postal Code
K1H 8L6
Country
Canada
Facility Name
Hopital Ste-Justine
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H3T 1C5
Country
Canada

12. IPD Sharing Statement

Links:
URL
http://www.novartisclinicaltrials.com
Description
Visit NovartisClinicalTrials.com: Pre-qualify for a trial, and view a list of trials and participating study centers.

Learn more about this trial

Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients

We'll reach out to this number within 24 hrs